In the subset of elderly diffuse large B-cell lymphoma (DLBCL), the concept of a sequential treatment with different targeted drugs and mechanisms and, at the same time, the reduction of conventional chemotherapy with its hematologic and extra-hematologic side effects, could represent the best therapeutic armamentarium in order to try to cure the majority of these patients. In this case, the roles of chemotherapy, immunotherapy and radioimmunotherapy as single approaches are well defined and absolutely positive. In this histological subset, it is very important to increase the rate of complete responses after induction and consolidation phases without any cumulative toxicity.
INTRODUCTION
Several studies have reported a significant advantage in adding rituximab to CHOP in elderly patients with a newly diagnosed diffuse large B-cell lymphoma (DLBCL), and in young patients with favorable prognostic profile (1) (2) (3) . Although the combination of Rituximab with CHOP (R-CHOP) as standard regimen has led to improved outcomes, there is a group of poor-risk patients which has a lower chance to be cured with standard R-CHOP, thus needing an alternative treatment strategy.
Two large randomized studies have clearly shown that the addition of Rituximab to CHOP given every 21 or 14 days has significantly improved the outcome in elderly patients (more than 60 years) compared to CHOP or CHOEP (i.e. with the addition of etoposide) but without rituximab. In the former GELA (Group d'Etude des Lymphomes de l'Adulte) study, patients were randomized to receive 8 courses of CHOP with or without rituximab every 21 days (1, 4) . R-CHOP21 significantly increased the complete response (CR) rate (76% vs 63%) and reduced the risk of treatment failure and death. The superiority of overall survival (OS) rate of R-CHOP was confirmed in both low-and highrisk age-adjusted International Prognostic Index (aaIPI) groups. However, the 5-years OS rate in high-risk patients did not exceed 50% even in patients treated with R-CHOP (48% vs 39%, comparing R-CHOP and CHOP). Similarly, the 5-years event-free survival (EFS) in high-risk patients was 41% vs 27%, again comparing R-CHOP and CHOP. In the latter study (Ricover 60), conducted by the German High Grade Non Hodgkin's Lymphoma Study Group (Deutsche Studiengruppe Hochmaligne Non-Hodgkin-Lymphome, DSHNHL), 1222 patients were randomized to receive six or eight courses of CHOP14 with or without rituximab and radiotherapy to sites of initial bulky disease (2). R-CHOP14 significantly improved 3-years EFS (66% vs 47%), progression-free survival (PFS), and OS if compared to six cycles of CHOP14 treatment.
A formal demonstration of whether R-CHOP14 is superior or not to R-CHOP21 is however still lacking. Randomized clinical trials between R-CHOP21 and R-CHOP14 are ongoing by GELA and British National Lymphoma Investigation (BNLI). The BNLI has recently reported some preliminary results on a phase III randomized trial comparing the two different schedules (462 patients in the R-CHOP21 arm and 481 in R-CHOP14): the radiological complete responses were 63% and 58% for each arm (5) . Therefore, the choice between R-CHOP21 and R-CHOP14, both considered as a standard therapy, of rituximab. At present, the optimal dose of rituximab has not yet been established:
rituximab serum levels build up slowly after infusion, and it might be possible that a dosedense immunotherapy could be able to improve the efficacy of the treatment. The aim of the "DENSE-R-CHOP14" trial was to explore a supplemented dose intense rituximab during the first 2 cycles of R-CHOP14 in elderly patients, maintaining a single dose in the subsequent cycles, for a total of 12 doses of rituximab delivered in 6 courses of chemotherapy. Rituximab serum levels resulted markedly increased, thus suggesting a higher efficacy in poor-risk patients, with a 1-yr EFS of 74%, against 65% related to the standard R-CHOP14 treatment. On the other hand, an increased incidence of infection was also documented, mainly interstitial pneumonia (6) . This strategy is currently under investigation in a controlled randomized study.
An innovative therapeutic option that should be investigated in order to increase patients' outcomes in poor prognosis DLBCL might be the addition of radioimmunotherapy.
The efficacy of the raioimmunoconjugate 90 Y-ibritumomab tiuxetan has been demonstrated in patients with relapsed or refractory aggressive DLBCL, with promising response rates and durable response (7) (8) (9) . Preliminary data from phase II studies in aggressive lymphomas (DLBCL and mantle cell lymphoma) suggest that 90 Y-ibritumomab tiuxetan is effective also in this disease setting, namely as consolidation treatment after chemotherapy or chemoimmunotherapy (10) (11) (12) .
Moving from these data and from our previous experience on the role of 90 Yibritumomab tiuxetan after CHOP in untreated high risk elderly DLBCL patients (11), we have designed a phase II trial aimed at increasing the global treatment efficacy including 90 Y-ibritumomab tiuxetan, along with a decreased exposure to cytotoxic drugs by using a short-course R-CHOP chemotherapy. In this trial, patients were to receive R-CHOP21 for 4 cycles, instead of 6 cycles, followed by treatment with 90 Y-ibritumomab tiuxetan.
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PATIENTS AND METHODS
Patients' eligibility and demography All patients were notified of the investigational nature of this study and signed a written informed consent approved in accordance with institutional guidelines, including the Declaration of Helsinki. The study has been approved by the institutional review board, and has been registered at ClinicalTrials.gov § , NCT00850512 .
All diagnostic biopsies were reviewed by an expert pathologist (S.P.) from our Institute, and then categorized in accordance with the WHO classification (14) .
Baseline studies
All the patients enrolled into this trial were required to undergo a full history, physical examination, complete blood cell count with leukocyte differential, platelet count, computed tomography (CT) scan of neck, chest, abdomen and pelvis (with and without contrast), Granulocyte colony-stimulation factor (G-CSF) was not administered in order to prevent neutropenia, according to our institution guidelines; patients who experienced grade 3 or 4 neutropenia or developed neutropenic fever between cycles of chemotherapy were allowed to receive growth factors, at the discretion of the treating physician.
Restaging
Patients were restaged 3 to 4 weeks after the completion of the fourth cycle of R-CHOP21 chemotherapy, through a complete physical examination, blood testing, CT scan, PET scan and bone marrow aspiration and biopsy (if bone marrow involvement was documented during baseline evaluation).
Responses were classified according to the revised response criteria for malignant lymphoma (15) .
Patients achieving at least a partial response (PR) after 4 cycles of R-CHOP21
were considered eligible for further consolidation with Safety and tolerability were evaluated by monitoring the incidence, severity, and type of any adverse event. Adverse events were defined according to the WHO criteria for toxicity.
Statistical analysis
The primary endpoint of this study was the assessment of the response rate Despite markedly superior outcomes in first-line treatment following the addition of rituximab to the CHOP regimen, with dose-dense/dose-intense regimens also playing a potential role (2, 3, 21-23), the prognosis for patients older than 60 still remains poor, with a 7-year OS rate of 53%, as reported in one study (21). At least 30% to 50% of these patients, with an advanced-stage DLBCL, will fail to attain a remission with primary therapy, or will experience disease relapse after achieving a remission. Occasionally, asymptomatic patients can be managed with a watch and wait approach if they are not candidates for aggressive therapy, and only selected patients may experience prolonged remissions with involved-field radiation therapy. However, the vast majority of patients will require a second-line (salvage) chemotherapy. Alternative treatment approaches should therefore be addressed at reducing the risk for disease relapse, for example by improving first-line therapeutic strategies, particularly in older patients not eligible for autotransplant.
Recently, on the basis of the "consolidation" concept experienced with Zinzani et al (11) Hamlin et al (12) This study 
